On Tuesday (May 15) CannTrust Holdings (TSX:TRST) unveiled its financial results for the first quarter of 2018, its first since joining the Toronto Stock Exchange (TSX) in March.

The company reported revenue of over C$7.8 million for the three month period that ended on March 31. In its revenue breakdown, CannTrust indicated dried cannabis managed to create over C$3 million, while extracts brought C$4,477,526.


CannTrust explained due to using the grow rooms from its Langstaff facility to harvest the mother plants for its brand new Niagara Greenhouse space, the company was required to purchase product from other cannabis producers in order to meet the demand for its products.

“Multiple harvests have now been completed at the Niagara Greenhouse Facility and these temporary third-party product purchases have now been replaced with home grown product,” the company said.

The reach of CannTrust’s products has increased since the active patient base for the company grew to over 40,000. During the quarter, the company sold 982,269 grams of cannabis.

According to the report, CannTrust has increased the expectations for the Niagara facility production capacity from 40,000 to 50,000 kilograms annually.

Optimistic outlook thanks to future production from Niagara facility

In a research note issued on Tuesday, Echelon Wealth Partners analyst Russell Stanley maintained his “Speculative Buy” rating on the company and set their one-year price target at C$18.50.

Despite falling short of his estimates, the company incurred one-time costs that, if taken away, would make its earnings before interest, tax, depreciation and amortization (EBITDA) on par with what Stanley had predicted.

“Given our view that dried cannabis will become increasingly commoditized, investors should favor companies that can develop and commercialize higher value products and/or deliver ultra-low production costs,” Stanley wrote.

The analyst wrote he expects the Niagara facility to provide a “meaningful contribution” to the company during the next quarter. This facility is also expected to have a phase two expansion, which Stanley wrote remains on track for mid-2018 completion.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

During Tuesday’s trading hours, shares of TRST decreased 3.40 percent to reach C$9.66 per share. According to data from Yahoo! Finance, since joining the TSX, CannTrust’s share price has increased 7.22 percent in value, indicating a C$0.65 gain for investors.

On the research analysts data site aggregator TipRanks, CannTrust currently has a “Moderate Buy” rating thanks to the opinion from two analysts. The one-year price target for TRST is C$17.25.

As part of the Investing News Network (INN) cannabis outlook for Q12018, a portfolio manager with Redwood Asset Management Greg Taylor said he was surprised the move from CannTrust to dump its US assets and move its stock to the TSX didn’t have a larger impact.

“Once this move was made, the TRST was uplisted to the TSX which I thought would be a major positive and the stock would see a re-rating higher,” Taylor told INN. “But it didn’t seem to be noticed by the market.”

Investor takeaway

Despite providing a moderately successful quarter, the nature of the cannabis industry has sparked conversations of acquisitions with most enterprises.

Fueled by the announcement from Aurora Cannabis (TSX:ACB) buying MedReleaf (TSX:LEAF) for C$3.2 billion, Midas Letter wrote on CannTrust:

More than the singularity of today’s gains, with MedReleaf officially taken out, CannTrust becomes the clear #1 prime asset in the lucrative medicinal market. With Aurora Cannabis establishing outright dominance, the odds of another suitor making an offer increase—and this should put a floor under the share price. The stock hasn’t been rising on a multi-day basis without reason.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less
  • Distinguished economist and former CEO of Ecopetrol, Colombia’s largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500
  • Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy
  • Adds proven economic and international business experience to boost the global growth of the Khiron business model
  • Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1 st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces that Mr. Juan Carlos Echeverry has been appointed to the Board of Directors of the Company, effective immediately. Mr. Echeverry brings extensive corporate, academic and macroeconomic experience, serving as Colombia’s Minister of Finance from 2010 to 2012 and as the CEO and President of Ecopetrol from 2015 to 2017.

Keep reading... Show less

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less